Minerva Neurosciences Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Minerva Neurosciences stock.
View analyst ratings for Minerva Neurosciences or view top-rated stocks.

Wall Street analysts have given Minerva Neurosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Minerva Neurosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Minerva Neurosciences saw a drop in short interest in the month of May. As of May 28th, there was short interest totaling 3,350,000 shares, a drop of 34.7% from the May 13th total of 5,130,000 shares. Based on an average trading volume of 1,470,000 shares, the days-to-cover ratio is presently 2.3 days. Approximately 8.1% of the company's stock are short sold.
View Minerva Neurosciences' Short Interest.

Minerva Neurosciences is scheduled to release its next quarterly earnings announcement on Monday, August 2nd 2021.
View our earnings forecast for Minerva Neurosciences.

Minerva Neurosciences, Inc. (NASDAQ:NERV) released its quarterly earnings results on Wednesday, May, 12th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.20 by $0.41.
View Minerva Neurosciences' earnings history.

Minerva Neurosciences' stock was trading at $6.36 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, NERV stock has decreased by 58.5% and is now trading at $2.64.
View which stocks have been most impacted by COVID-19.

3 brokers have issued 1-year target prices for Minerva Neurosciences' shares. Their forecasts range from $9.00 to $10.00. On average, they anticipate Minerva Neurosciences' stock price to reach $9.50 in the next year. This suggests a possible upside of 259.8% from the stock's current price.
View analysts' price targets for Minerva Neurosciences or view top-rated stocks among Wall Street analysts.

Some companies that are related to Minerva Neurosciences include MedAvail (MDVL), Athenex (ATNX), Akouos (AKUS), Spero Therapeutics (SPRO), Geron (GERN), Viracta Therapeutics (VIRX), BeyondSpring (BYSI), KemPharm (KMPH), Neoleukin Therapeutics (NLTX), Oramed Pharmaceuticals (ORMP), Oncorus (ONCR), Amryt Pharma (AMYT), ANI Pharmaceuticals (ANIP), Kindred Biosciences (KIN) and Homology Medicines (FIXX).
View all of NERV's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Minerva Neurosciences investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), PTC Therapeutics (PTCT), Immunomedics (IMMU), VBI Vaccines (VBIV), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Moderna (MRNA), T2 Biosystems (TTOO) and Advanced Micro Devices (AMD).

Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."

Minerva Neurosciences' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (5.46%), Acadian Asset Management LLC (4.08%), Dimensional Fund Advisors LP (2.55%), Goldman Sachs Group Inc. (2.24%), Morgan Stanley (2.17%) and Armistice Capital LLC (2.13%). Company insiders that own Minerva Neurosciences stock include David Kupfer, Frederick W Ahlholm, Geoff Race, Heek G Jan Van, Joseph H Reilly, Remy Luthringer and Venture Associates L Index III.
View institutional ownership trends for Minerva Neurosciences.

NERV stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Russell Investments Group Ltd., Dimensional Fund Advisors LP, Walleye Capital LLC, Goldman Sachs Group Inc., AQR Capital Management LLC, Northern Trust Corp, and Alliancebernstein L.P.. Company insiders that have sold Minerva Neurosciences company stock in the last year include Frederick W Ahlholm, Geoff Race, Joseph H Reilly, and Remy Luthringer.
View insider buying and selling activity for Minerva Neurosciences or view top insider-selling stocks.

NERV stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, Assenagon Asset Management S.A., Armistice Capital LLC, Los Angeles Capital Management LLC, Millennium Management LLC, BlackRock Inc., Geode Capital Management LLC, and Price T Rowe Associates Inc. MD. Company insiders that have bought Minerva Neurosciences stock in the last two years include David Kupfer, and Heek G Jan Van.
View insider buying and selling activity for Minerva Neurosciences or or view top insider-buying stocks.

Shares of NERV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NERV stock can currently be purchased for approximately $2.64.

Minerva Neurosciences has a market capitalization of $112.79 million and generates $41.18 million in revenue each year. The biopharmaceutical company earns $1.94 million in net income (profit) each year or $0.05 on an earnings per share basis.

Minerva Neurosciences employs 11 workers across the globe.

The official website for Minerva Neurosciences is www.minervaneurosciences.com.

Minerva Neurosciences is headquartered at 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451.

Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-600-7373 or via email at [email protected]